Scleritis With Uveal Effusion From Alirocumab
Authors: Mark P. Breazzano, Royce W.S. Chen
Journal: Annals of Internal Medicine (2020)

Letters16 June 2020Scleritis With Uveal Effusion From AlirocumabMark P. Breazzano, MD and Royce W.S. Chen, MDMark P. Breazzano, MDColumbia University Irving Medical Center, New York–Presbyterian Hospital, New York University School of Medicine, and University Langone Health, New York, New York (M.P.B.) and Royce W.S. Chen, MDColumbia University Irving Medical Center, New York–Presbyterian Hospital, New York, New York (R.W.C.)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/L19-0815 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Background: Alirocumab is a human monoclonal antibody that belongs to a novel class of drugs known as proprotein convertase subtilisin/kexin type 9 inhibitors that increase the expression of low-density lipoprotein receptor and decrease levels of low-density lipoprotein cholesterol (1). It is used as a second-line treatment for high cholesterol levels in adults whose hypercholesterolemia is not controlled by diet and statin treatment. To our knowledge, alirocumab has not been reported to cause scleritis.Objective: To alert clinicians to the possibility that alirocumab may cause scleritis with uveal effusion.Case Report: A 63-year-old woman had several weeks of increasing pain, redness, ...References1. Masson W, Lobo M, Huerín M, et al. Plasma proprotein convertase subtilisin/kexin type 9 inhibitors and cataract risk: a systematic review and meta-analysis. Arch Soc Esp Oftalmol. 2019;94:75-80. [PMID: 30502968] doi:10.1016/j.oftal.2018.11.003 CrossrefMedlineGoogle Scholar2. Toussirot É, Aubin F. Paradoxical reactions under TNF-a blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview. RMD Open. 2016;2:e000239. [PMID: 27493788] doi:10.1136/rmdopen-2015-000239 CrossrefMedlineGoogle Scholar3. Michael E, Lange EL, Guest S. Paradoxical nodular scleritis during tocilizumab therapy: a case report [Letter]. J Rheumatol. 2017;44:1760-1761. [PMID: 29093079] doi:10.3899/jrheum.170234 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Columbia University Irving Medical Center, New York–Presbyterian Hospital, New York University School of Medicine, and University Langone Health, New York, New York (M.P.B.)Columbia University Irving Medical Center, New York–Presbyterian Hospital, New York, New York (R.W.C.)Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L19-0815.This article was published at Annals.org on 10 March 2020. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byAlirocumab 16 June 2020Volume 172, Issue 12Page: 834-836KeywordsDisclosureIntraocular pressureLow density lipoproteinMonoclonal antibodiesStatinsThyroidUltrasound imagingUveitisVisionVisual acuity ePublished: 10 March 2020 Issue Published: 16 June 2020 Copyright & PermissionsCopyright © 2020 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...